linkedin post 2013-06-21 04:25:47
RARE DISEASE FUND by GSK is a trend we see increasingly today. A decade ago, rare diseases were a very hard sell to VCs or Pharma. With the easier big disease targets solved with drugs like statins, and despite newly invented diseases like ED and RLS, the traditional target pool is diminishing. However, we have not yet seen the rise of Intelligent Drugs: making good drugs perform better by using smart materials that are responsive to the environment. Smart drugs can increase compliance, thus efficacy, and be more patient-centric just as the medical paradigm is changing. Watch this space! http://lnkd.in/3ASxtj View in LinkedIn